Dr. Judy Hsiung is currently Senior Medical Director, Global Pharmacovigilance and Risk Management at Halozyme Therapeutics, where she is Head of Safety Sciences and responsible for leading a team charged with signal detection, aggregate safety reports and risk management for all compounds, both in development and marketed in the organization. She has extensive experience with worldwide regulatory agencies. Previously, she was Acting Head of Global Medical Safety at Otsuka Pharmaceuticals as well as Director of Risk Management at CSL Behring Inc. As Global Safety Leader at Bayer Schering Pharma, she led Safety submission strategy for a key indication of a novel oral anticoagulant, now marketed for several indications worldwide. While at BSP, she also was a facilitator and a key member of the Core Management Team in developing strategy for ideal benefit-risk lifecycle product management as well as risk management planning for EU and Core RMPs for multiple compounds in indications including Oncology and CV-Hematology. Dr. Hsiung started her 17 year career in Pharmavigilance/Risk Management as a Senior Drug Safety Associate at Hoffmann La Roche, where she primarily worked with a team of epidemiologists oon risk management for Accutane. She also collaborated on the AVDAC for an anti-infectives compound, now marketed for Hepatitis C. Later in her career, she served as a Senior Clinical Safety Scientist at Bristol Myers Squibb, where she authored aggregate safety reports for all products in the Oncology TA.